Related TEVATeva Still A ‘Must-Own’ Stock, Worth $86Benzinga’s Top UpgradesWeekly 52-Week Highs Highlight: GIS, AAP, BCR, TEVA(GuruFocus)Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) surged to new 52-week highs of $69.42 on Monday after the company announced its acquisition of Allergan PLC (NYSE: AGN)’s Generics segment for a total consideration of $40.5 billion.Shares of Allergan also spiked to new […]
By Steve SearsGoldman Sachs is telling clients to hedge the bio-technology sector in anticipation of a sharp decline. Early Monday, the bank told clients to buy SPDR S&P Biotech ETF (XBI) December $230 puts. During the pre-market, the ETF was priced at $255, and the put was at $15.50.
SSPL via Getty Images
“These puts are about 10% out-of-the-money and cost about […]
Anacor Pharmaceuticals (NASDAQ:ANAC)On Monday July 13, 2015 shares of Anacor went up 55%, closing around $131.93 per share after the company announced positive phase 3 results in patients who have atopic dermatitis. There were two phase 3 trials that were testing Anacor’s drug, Crisaborole, for these patients with atopic dermatitis — also known as Eczema. The company wanted to see […]
By Johanna BennettDo you want safe, or sexy?That’s the question facing biotechnology investors, according to a recent research note from Cowen analysts that previews the sector’s second-quarter financial results.“In heady times, large cap provides a safe haven, smid caps the sex appeal,” reads the note.After shrugging off a selloff in late June, the Nasdaq Biotechnology index has gained 30% since […]
SummaryAs an update from my previous article, I am reviewing some European biotech picks and introducing new favorites.
Owing to strong fundamentals and an increasing number of significant deals in the sector, a technologically diversified, European biotech portfolio makes more sense now than ever.
The main investment thesis remains that leading small-cap European biotechs are reaching maturity and present a great value […]
Janet Yellen is facing Congress on Wednesday for her semi-annual testimony.And one year ago today, Yellen’s monetary policy report warned about stock market valuations, particularly in social media and biotech stocks. It was an awful call. Yellen’s testimony last year said:”Some broad equity price indexes have increased to all-time highs in nominal terms since the end of 2013. However, valuation measures for the overall market in […]
Markets are rebounding today after a horrible beginning to the week. Looking in the biotech sector, I’m seeing a sea of green with very few blemishes. I’ve also been able to dig out a few great opportunities in the sector. Here they are…Gilead Sciences Is Likely To See Long Run GainsGilead Sciences, Inc. (NASDAQ: GILD)I’ve talked about Gilead Sciences quite […]
(NaturalNews) If you’re trying to understand today’s stock market and are having some degree of difficulty, you’re not alone.The markets are confusing enough sometimes for experts, so they can be particularly baffling for laypersons. Still, a few economic basics ought to be pretty simple to understand, right?Wrong – apparently.About a year ago, as documented by the Zero Hedge website, Federal […]
Biotechs rise on Greece ‘No’ Vote!Amazing news, right? I mean, who would think the news out of Greece would push biotech stocks higher?But apparently it did. The Greek people let the world know they ain’t interested in more austerity (not that they really had any). Meanwhile, biotechs were the strongest group of stocks on the market to kick off the […]
One of the most popular and well-known names in the biotech world is definitely Biogen (BIIB-Analyst Report). This large cap stock has been a staple of investor portfolios in the biotechnology space for some time, while it is also one of the behemoths of the sector, closing in on $100 billion in market cap.BIIB might be due for a breather […]
